BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on Monday, November 29.
BioNTech SE said it had started work on a vaccine tailored to Omicron, along with partner Pfizer.
Moderna Inc said it could take months to begin shipping such a vaccine.
Johnson & Johnson is also evaluating the effectiveness of its COVID-19 vaccine against Omicron, while also pursuing a vaccine specific to the variant.
The variant’s emergence has triggered a strong global response as countries worry that it could spread fast even in vaccinated populations.